BEDFORD, Mass--(BUSINESS WIRE)--Mar. 8, 2017--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that it will
report financial results for the fourth quarter and full year ended
December 31, 2016, on Friday, March 10, 2017. Following distribution of
the earnings release via wire services, the Ocular management team will
host a live conference call and webcast at 8:30 a.m. Eastern Time to
review the Company’s financial results and provide a general business
The live webcast can be accessed by visiting the investor section of
Ocular’s website at investors.ocutx.com.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call 844-464-3934
(U.S.) or 765-507-2620 (International) to listen to the conference call.
The conference ID number for the live call will be 77324558. An archive
of the webcast will be available until March 24, 2017 on the company’s
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix has resubmitted a new drug application
(NDA) for post-surgical pain for its lead product candidate, DEXTENZA
(dexamethasone insert), which has completed Phase 3 clinical development
for ocular pain and inflammation following ophthalmic surgery, and the
Company is pursuing additional indications for DEXTENZA. OTX-TP
(sustained release travoprost) is in Phase 3 clinical development for
glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating
injectable drug delivery depots for back-of-the-eye diseases. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved
to seal corneal incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170308005711/en/
Source: Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
Cynthia Sutherland, 646-599-8635
Media Group Director
Vice President of Marketing &